A Single-Arm, Open-Label Study to Assess the Immunogenicity, Safety, and Efficacy of Etanercept Manufactured Using the High Capacity Process Administered to Subjects with Rheumatoid Arthritis To assess the immunogenicity of etanercept manufactured using the high capacity process administered weekly in subjects with RA over 24 weeks.

• Country None
• organs None
• Specialty None

STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 04236921 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) The primary objective of this study is to evaluate and compare the efficacy of 3 dose levels of PF-04236921 to placebo in subjects with active SLE using the SLE Responder Index (SRI).

• Country None
• organs None
• Specialty None

A study to assess the efficacy, safety and tolerability of PF-04950615 following monthly and twice monthly injection dosing for six months in subjects on a statin with high cholesterol To evaluate the LDL-C lowering effect of PF-04950615 administered subcutaneously at monthly intervals, or twice monthly intervals in hypercholesterolemic subjects whose LDL-cholesterol is ≥80 mg/dL on...

• Country None
• organs None
• Specialty None

A study to find out if a vaccine designed to protect against a disease (group B meningococcal meningitis) is safe and protects children aged from 24 months to less than 10 years •To describe the immune response as measured by hSBA performed with 4 primary MnB test strains, 2 expressing an LP2086 subfamily A protein and 2 expressing an LP2086 subfamily B protein, measured 1 mo...

• Country None
• organs None
• Specialty None

RANDOMIZED, DOUBLE-BLIND, 12-MONTH STUDY OF PREGABALIN IN SUBJECTS WITH RESTLESS LEGS SYNDROME • To assess the efficacy of a fixed dose of pregabalin to placebo during the first 12 week treatment period in subjects with RLS. • To compare the rate of augmentation of a fixed dose of pregabalin t...

• Country None
• organs None
• Specialty None

A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 26-WEEK TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DIMEBON (LATREPIRDINE, PF-01913539) IN PATIENTS WITH MODERATE-TO-SEVERE ALZHEIMER’S DISEASE The co-primary objectives of this study are: 1. To determine the effect of dimebon, as compared to placebo, on the primary measure of cognition, the Severe Impairment Battery (SIB) in patients with mo...

• Country None
• organs None
• Specialty None

Study with investigational drug PF-06463922 in patients with a specific type of advanced lung cancer Estudio con fármaco en investigación PF-06463922 en pacientes con un tipo específico de cáncer de pulmón This study has separate primary objectives for the two study portions: Phase 1 and Phase 2. Phase 1 study portion: To assess safety and tolerability of PF-06463922 as a single agent at increasing dose...

• Country None
• organs None
• Specialty None

A MULTIPLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS AND/OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA ESTUDIO CON MÚLTIPLES DOSIS PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD, LA FARMACOCINÉTICA, LA FARMACODINÁMICA Y LA EFICACIA DE LA ADMINISTRACIÓN DE PF-06741086 POR VÍA SUBCUTÁNEA O INTRAVENOSA EN SUJETOS CON HEMOFILIA GRAVE To determine the safety and tolerability of multiple doses of PF-06741086 administered to severe hemophilia A and B subjects. Determinar la seguridad y la tolerabilidad de múltiples dosis de PF ...

• Country None
• organs None
• Specialty None

PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF CP 690,550 MONOTHERAPY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS 1. To compare the efficacy of CP 690,550, as monotherapy, in doses of 5 mg BID and 10 mg BID versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA), in subjects with RA wh...

• Country None
• organs None
• Specialty None

A clinical trial to evaluate whether a potential new drug is an effective and safe way to make damaged kidneys work better in patients with type II diabetes To evaluate the efficacy of PF-00489791 in the reduction of albuminuria in subjects with type 2 diabetes and overt nephropathy.

• Country None
• organs None
• Specialty None